Clovis Oncology, Inc. (NASDAQ:CLVS) is reporting first quarter financial results on Tuesday 8th May 2018, after the bell.
According to analysts surveyed by Thomson Reuters, CLVS is expected to report 1Q18 loss of $ 1.36 per share from revenue of $ 18.33 million.
The same period from last year, CLVS reportedly had loss of $ 1.33 per share on $ 7.04 million in revenue.
For the full year, analysts anticipate top line of $ 148.80 million, while looking forward to loss of $ 4.81 per share bottom line.
About Clovis Oncology, Inc.
|% Change from 52 Week Low|
|% Change from 52 Week High|